Hi All, this is probably a silly question but Ph1 trials are primarily about safety and ascertaining optimal dosage levels; without wanting to ignore any efficacy findings - Is it at all possible that if safety protocols are satisfactorily passed can future Ph.2 trials use cohorts that haven’t had their immune systems compromised by chemotherapy or other current SOC?
- Forums
- ASX - By Stock
- IMU
- Ann: First patient dosed in Phase 1 bile tract cancer trial
Ann: First patient dosed in Phase 1 bile tract cancer trial, page-134
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $396.8M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 5.3¢ | $339.4K | 6.365M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 895592 | 5.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.4¢ | 672708 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 845592 | 0.053 |
21 | 2719942 | 0.052 |
37 | 3800174 | 0.051 |
70 | 5690066 | 0.050 |
16 | 2155346 | 0.049 |
Price($) | Vol. | No. |
---|---|---|
0.054 | 672708 | 10 |
0.055 | 2964674 | 13 |
0.056 | 2227496 | 13 |
0.057 | 1068065 | 8 |
0.058 | 725800 | 5 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online